Biopharma Out-licensing: 2012’s “In” Thing?
By
Ellen Foster Licking (Contributor) / Email the Author / IN VIVO January 2012, Vol. 30, No. 1
Around The Industry / Word Count: 1013 / Article # 2012800006
Executive Summary
Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing? An analysis by IN VIVO suggests yes – but with qualifications.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.